Testosterone for Menopause: What the Evidence Actually Shows

Testosterone is often labeled a 'male' hormone, but women produce it too, and in younger women the ovaries and adrenal glands make several times more testosterone than estrogen by quantity. Levels decline gradually with age, and after menopause the ovaries produce less of it. The hormone plays a role in sexual desire, arousal, and the sense of sexual well-being, and it contributes to energy, mood, and muscle and bone maintenance. Because of these wide-ranging roles, testosterone is frequently marketed as a fix for fatigue, brain fog, and low motivation in midlife. But here's the crucial distinction the research draws: the *only* symptom for which testosterone has solid, high-quality evidence in postmenopausal women is low sexual desire that causes distress, formally called hypoactive sexual desire disorder (HSDD). For everything else, the science isn't there yet, which doesn't mean it can't help individuals, only that we lack the trial evidence to recommend it broadly.

Yes, this is the strongest part of the evidence. The 2019 Global Consensus Position Statement on Testosterone Therapy for Women (published simultaneously in four journals and endorsed by 11 international medical societies, including the International Menopause Society and ISSWSH) reviewed the randomized controlled trial data and concluded that systemic testosterone, at doses producing female-physiologic levels, significantly improves sexual desire, arousal, orgasm, and sexual satisfaction in postmenopausal women with HSDD. The improvements are modest but real and meaningful for women experiencing distressing loss of desire. The statement was deliberately specific: it endorsed testosterone *only* for HSDD and *only* when other contributing factors (relationship issues, medications like SSRIs, untreated menopause symptoms, mood disorders) have been addressed first. This is why a good clinician treats the whole picture: if painful sex from vaginal dryness or poor sleep from night sweats is dampening desire, those need attention too, sometimes alongside or even instead of testosterone.

This is where expectations and evidence diverge. Many women are prescribed testosterone hoping it will lift fatigue, sharpen focus, stabilize mood, or rebuild muscle. The 2019 Global Consensus Statement explicitly found insufficient evidence to recommend testosterone for any of these non-sexual outcomes, including cognitive performance, mood, bone density, energy, and general well-being. That doesn't mean testosterone *never* helps these symptoms in any individual, and some women do report broad improvements. But the controlled-trial data can't yet separate a true hormonal effect from placebo or from the indirect lift of having a better sex life. The honest framing is: if your main complaint is fatigue or brain fog, the better-studied first steps are optimizing estrogen therapy (which has good evidence for many menopause symptoms), sleep, iron and thyroid status, strength training, and stress. Testosterone may be considered, but it shouldn't be the headline treatment for non-sexual symptoms. Our guides on menopause brain fog and HRT options cover the better-evidenced approaches.

When dosed correctly, the safety record is reassuring. The key principle is female-physiologic dosing, meaning doses that restore testosterone to the normal premenopausal range, roughly one-tenth of a typical male dose. At these levels, the Global Consensus Statement found testosterone is generally well tolerated. The most common side effects are mild and dose-dependent: acne and increased body or facial hair at the application site. More serious masculinizing effects (voice deepening, clitoral enlargement, scalp hair loss) are rare and signal that the dose is too high, which is why monitoring blood levels matters. Reviewed trials up to about two years did not show harmful effects on cholesterol when testosterone was given through the skin (transdermal) rather than orally; oral testosterone is not recommended because it can negatively affect lipids. Long-term data on breast and cardiovascular safety beyond a couple of years is still limited, so testosterone is used thoughtfully, with the lowest effective dose and periodic monitoring. Women with a history of hormone-sensitive cancers should discuss individualized risk with their specialist.

This is the practical sticking point. In the United States, there is no FDA-approved testosterone product designed for women, so clinicians prescribe it off-label, typically using a small, measured fraction of an FDA-approved male transdermal gel or a compounded preparation. (In the UK and Australia, women often use a fraction of a licensed male product, and Australia has an approved female cream.) Because it's off-label in the US, not every provider is comfortable prescribing it, and you may need a menopause specialist or a telehealth menopause service. If you pursue it, look for a clinician who will dose to female-physiologic levels, monitor your blood testosterone, and use a transdermal (skin) route rather than pellets or injections, which can cause levels to spike too high. Testosterone is usually added on top of standard menopause hormone therapy rather than used alone, so it fits into a broader plan that may include estrogen and, if you have a uterus, progesterone. Because the landscape is nuanced, this is a conversation to have with a knowledgeable provider rather than a DIY project.